News

PolyMedix has completed a second clinical study of its anticoagulant reversing agent, PMX-60056. The phase 1B clinical study was a pilot proof-of-concept study conducted in the US under

Alkermes has initiated phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly

BioMarin Pharmaceutical has acquired Huxley Pharmaceuticals, which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

We are looking to find out how readers are expecting the market to perform into 2010, what will be the key sectors, trends and spending areas, and where

The US Food and Drug Administration (USFDA) has approved Indus Biotech to conduct clinical trails for its molecule, IND02, reported The Economic Times. The newly developed molecule is

Romaco has presented the vertical heat-sealing machine – Siebler HM 1/230 – for strip-packaging of pharmaceutical solids such as tablets, capsules and effervescent tablets at P-MEC 2009. The

Genmab has reached a milestone for Arzerra (ofatumumab) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately $23m was triggered by the FDA

The FDA has reviewed and has allowed the use of twelve new structural health claims filed for Algatechnologies’ AstaPure brand of natural astaxanthin in the US market. Reportedly,

Pursuant to the terms of the agreement, Sequenom agreed to grant Ibis Biosciences and its affiliates, including Abbott Laboratories, a non-exclusive license under the three mass spectrometry-based patents